drugset / Trial / NCT04964089
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
RandomizedParallel-groupTriple-blindTreatment
Summary
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
Timeline
- Start
- 2021-06-23
- Primary completion
- 2023-03-28
- Completion
- 2023-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Tarcocimab tedromer | Protein / enzyme biologic | 5 mg | Intravitreal |